Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CytoMed TherapeuticsFRA:F98 -9.58%19 PS Ratio is 39.74 as of Jul. 25, 2026, which is 89% below its 10-year median of 375.00. GuruFocus rates FRA:F98 with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 929 Biotechnology companies, CytoMed Therapeutics ranks worse than 76.21% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, CytoMed Therapeutics's share price is €0.755.
CytoMed Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.02. Hence, CytoMed Therapeutics's PS Ratio for today is 39.74.
The historical rank and industry rank for CytoMed Therapeutics's PS Ratio or its related term are showing as below:
FRA:F98'
s PS Ratio Range Over the Past 10 Years
Min: 35.45 Med: 375 Max: 690
Current: 45
During the past 6 years, CytoMed Therapeutics's highest PS Ratio was 690.00. The lowest was 35.45. And the median was 375.00.
FRA:F98's PS Ratio is ranked worse than 76.21% of 929
companies
in the Biotechnology industry
Industry Median: 9.13
vs FRA:F98: 45.00
CytoMed Therapeutics (FRA:F98) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
CytoMed Therapeutics PS Ratio Related Terms
CytoMed Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for CytoMed Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CytoMed Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoMed Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where CytoMed Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
CytoMed Therapeutics's Share Price of today is €0.755.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CytoMed Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
CytoMed Therapeutics (FRA:F98) has a PS Ratio of 39.74 as of Jul. 25, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on CytoMed Therapeutics and its competitors. This is 89% below median its historical median of 375.00. Over the past decade, CytoMed Therapeutics' PS Ratio has ranged from 35.45 to 690.00. According to the industry distribution chart, CytoMed Therapeutics ranks #708 out of 929 companies in the Biotechnology industry, placing it in the top 76.2%.
Is CytoMed Therapeutics' PS Ratio too high?
CytoMed Therapeutics' current PS Ratio of 39.74 is 89% below median its 10-year median of 375.00. Over the past 10 years, this metric has ranged from a low of 35.45 to a high of 690.00. The Biotechnology industry median PS Ratio is 9.13. CytoMed Therapeutics' value of 39.74 is 335.3% above this industry median. Based on the distribution chart, CytoMed Therapeutics ranks #708 out of 929 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CytoMed Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does CytoMed Therapeutics' PS Ratio compare to LEXX and INAB?
According to the Biotechnology industry distribution chart, CytoMed Therapeutics ranks #708 out of 929 companies for PS Ratio. This places CytoMed Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.13. CytoMed Therapeutics' value of 39.74 is 335.3% above this benchmark. Historically, CytoMed Therapeutics' own PS Ratio has ranged from 35.45 to 690.00 over the past decade. While the company's 10-year median is 375.00 vs. the industry median of 9.13, CytoMed Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.13, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CytoMed Therapeutics's current PS Ratio of 39.74 is 335.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on CytoMed Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytoMed Therapeutics's current PS Ratio is 39.74, which is 89% below median its own 10-year median of 375.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoMed Therapeutics stock overvalued right now?
CytoMed Therapeutics (FRA:F98) has a current PS Ratio of 39.74. The current PS Ratio is 39.74, which is 89% below median its 10-year median of 375.00 and 335.3% above the Biotechnology industry median of 9.13. CytoMed Therapeutics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For CytoMed Therapeutics (FRA:F98), the current PS Ratio is 39.74 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
19GF Score
Get the complete analysis for FRA:F98
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:F98 has been successfully added to your 
